Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year

Lilly Omvoh (mirikizumab-mrkz) has produced multidimensional treatment outcomes at one year in both ulcerative colitis (UC) and Crohn’s disease, according to new post-hoc analyses announced by Eli Lilly and Company (NYSE: LLY) on October 15, 2026. The Indianapolis-based drugmaker said patients with moderately to severely active disease achieved several treatment goals at once, including patients who had previously failed a biologic therapy.

In the LUCENT-2 maintenance study, 27.7% of Lilly Omvoh treated UC patients reached comprehensive disease control, a novel composite outcome. In VIVID-1, 20.4% of Omvoh treated Crohn’s patients reached corticosteroid free deep remission. Lilly also reported that reaching these endpoints was associated with better patient reported outcomes across both forms of inflammatory bowel disease (IBD).

More than one third of patients in the UC analysis (35.3%) and nearly half of those in the Crohn’s analysis (48.6%) had experienced prior biologic treatment failure, a group that often faces greater treatment challenges. The post-hoc Lilly Omvoh data from the LUCENT and VIVID programs will be presented at United European Gastroenterology (UEG) Week 2026. Lilly framed the findings as part of an evolution in IBD treatment goals toward a more holistic, patient centered approach that goes beyond clinical remission.

What the New Lilly Omvoh Data Mean for IBD Treatment Goals

Anabela Cardoso, senior vice president of Lilly Immunology Medical Affairs, said the results show that “a higher bar for disease control is achievable.” She noted that IBD treatment is often measured one endpoint at a time, whereas these analyses show patients meeting several goals together at one year, along with better reported quality of life.

Learn More

Charles River Magellan Collaboration Backs Zelestrocel Osteoarthritis Therapy With cGMP NGS Viral Safety Testing

Stefan Schreiber, M.D., of University Hospital Schleswig-Holstein and Christian-Albrecht University of Kiel, described the endpoints as “a meaningful shift in how we define treatment success.” He added that the outcomes seen across the LUCENT and VIVID programs were also observed in patients with prior biologic failure.

A comprehensive approach to IBD management weighs the symptoms patients feel, what clinicians can objectively measure and how disease affects daily life. Lilly cited previously published real world studies associating improvement across several dimensions with a lower risk of flares, steroid use, hospitalization and surgery over time. Lilly Omvoh is the product at the center of that broader measurement approach in this release.

Release Snapshot:

Lilly Omvoh Comprehensive Disease Control in Ulcerative Colitis

Comprehensive disease control is a novel composite outcome informed by an international expert consensus published in the Journal of Crohn’s and Colitis. It combines clinical remission, no corticosteroid use for at least 12 weeks before Week 52, histologic remission and fecal calprotectin of 250 μg/g or lower. Lilly states that Lilly Omvoh is the first IL-23p19 inhibitor evaluated for this endpoint in UC.

Learn More

Roche Tecentriq Colon Cancer Milestone: FDA Approves Tecentriq and Tecentriq Hybreza With Chemotherapy for Stage III dMMR Disease

The analysis was post hoc and covered patients who responded to Omvoh at Week 12 of the LUCENT-1 induction study and were then re-randomized in LUCENT-2 to continue Omvoh or receive placebo. Patients assigned to placebo had discontinued Omvoh for the maintenance period, so the comparison reflects continued treatment versus withdrawal at 52 weeks from induction baseline.

At one year, 27.7% of Omvoh treated patients achieved comprehensive disease control versus 14% on placebo. Among patients with prior biologic failure, the rates were 23.4% for Omvoh and 9.4% for placebo. Lilly did not disclose patient numbers per arm, confidence intervals or p-values in the release.

Lilly Omvoh UC Results (LUCENT-2, Week 52):

Quality of life findings stood out. Among Omvoh treated patients, 91.1% of those who reached comprehensive disease control also reached remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), compared with 65.2% of those who did not. Those achieving the endpoint were also more likely to report no to minimal bowel urgency and greater improvements in work productivity.

Lilly Omvoh Corticosteroid Free Deep Remission in Crohn’s Disease

In Crohn’s disease, corticosteroid free deep remission combines clinical remission measured by the Crohn’s Disease Activity Index, endoscopic remission and no corticosteroid use for at least 12 weeks before Week 52. VIVID-1 was a Phase 3, randomized, double blind, placebo controlled 52 week study in adults. Patients on Omvoh received 900 mg intravenously at Weeks 0, 4 and 8, then 300 mg subcutaneously at Week 12 and every four weeks for 40 weeks.

At one year, 20.4% of patients receiving Lilly Omvoh achieved corticosteroid free deep remission versus 2% on placebo. Among patients with prior biologic failure, 15.7% on Omvoh reached the endpoint while none on placebo did. Placebo patients who did not respond by Week 12 switched to Omvoh and were counted as non responders in this analysis.

Lilly Omvoh Crohn’s Disease Results (VIVID-1, Week 52):

Lilly Omvoh Safety Profile, Approvals and Combination Pipeline

Lilly said the safety findings from the Phase 3 programs were reported previously. In LUCENT-1 and LUCENT-2, the most common adverse reactions were upper respiratory tract infections, injection site reactions, arthralgia, rash, headache and herpes viral infection. In VIVID-1, they were upper respiratory tract infections, injection site reactions, headache, arthralgia and elevated liver tests.

The Important Safety Information lists a contraindication for patients with a history of serious hypersensitivity to mirikizumab-mrkz or its excipients. Warnings cover hypersensitivity reactions including anaphylaxis, infections, tuberculosis evaluation before treatment, hepatotoxicity with liver monitoring for at least 24 weeks, and avoiding live vaccines. Clinicians should consult the full label before prescribing.

Omvoh is approved for moderately to severely active UC and Crohn’s disease in adults and has reached approval in 47 countries. It is also approved as a single injection maintenance regimen for adults with UC in several countries, including the U.S., EU, Canada and Japan. Omvoh is an IL-23p19 antagonist that selectively targets the p19 subunit of IL-23, a pathway whose over activation plays a critical role in IBD pathogenesis, according to Lilly.

Looking ahead, Lilly is pursuing combination studies of mirikizumab, which are forward looking and carry no guarantee of success. These include UC studies with eltrekibart and zotemtegrast, and a Crohn’s study with an FXR agonist. The COMMIT-UC trial and COMMIT-CD trial examine mirikizumab alongside an incretin based therapy in adults with obesity or overweight and a weight related comorbidity. Pediatric studies are also ongoing. Lilly Omvoh remains central to that pipeline strategy.

Mirikizumab Studies Named in the Release: